Genmab — April 2024
-
Highlights from ESMO 2023: Antibody-drug conjugates and bispecific T-cell engagers
At ESMO 2023, much of the focus was on new data for antibody-drug conjugates (ADCs) and bispecific T-cell engagers (BiTEs)
Clinical Trials Arena (www.clinicaltrialsarena.com)
-
Thanks E L 09:48. Can you also see what’s the forecast for epcoritamab is by 2030?
-
'GlobalData’s consensus forecast forecasts that Epkinly will achieve blockbuster status by 2027, with global sales expected to exceed $1.9bn by 2029.' from may last year https://www.clinicaltrialsarena.com/analyst-comment/abbvie-genmab-epkinly-dlbcl/?cf-view
-
Due to Epkinly's tremendous efficacy, analysts at SVB Securities think that the drug could reach peak annual sales of $3 billion in the U.S. https://www.nasdaq.com/articles/could-this-new-drug-be-a-blockbuster-for-these-2-pharma-collaborators
-
Sydbank epcoritamab
He estimates the new drug’s annual peak sales potential at USD 3.5bn.https://medwatch.com/News/Pharma___Biotech/article15855008.ece -
Drug: Epcoritamab
Companies: AbbVie and Genmab
Used for: Lymphoma
Est. 2028 sales: $1.7 billion https://www.fiercepharma.com/marketing/top-10-most-anticipated-drug-launches-2023 -
Thanks E L. Do you know how the forecasters see the market share split between epco versus glofi/monesu? 50/50?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind